Scaling UK Healthtech in the United States: Why New Jersey Should Be Your Launchpad

Healthtech companies from the UK are looking to enter the U.S. market to capture the vast opportunities this move presents.

One of the most effective ways to de-risk expansion is to choose the right first state. For UK innovators seeking hospital pilots, diverse patient populations, and a credible springboard into the wider U.S. market, New Jersey stands out as an ideal launchpad.

Leading Health Systems in New Jersey

Success in the U.S. begins with clinical validation and provider adoption. New Jersey offers access to nationally ranked health systems within a compact, highly connected geography.

The state is home to RWJBarnabas Health and Hackensack Meridian Health, two of the largest and most respected providers in the region. Hospitals within these systems are regularly recognized in U.S. News & World Report’s annual rankings, underscoring their strength across specialties, including cardiology, oncology, orthopedics, and neurology.

Critically for oncology-focused innovators, New Jersey is also home to the Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center. UK companies developing cancer diagnostics, digital therapeutics, genomics platforms, or AI-enabled imaging tools have access to world-class research and clinical trials infrastructure in New Jersey.

Structural Advantages for UK Companies in New Jersey

A highly diverse patient population

New Jersey is one of the most demographically diverse states in the United States. For companies needing representative clinical datasets and validation across varied ethnic, socioeconomic, and clinical profiles, the state provides a realistic microcosm of the broader world.

A dense but navigable medical community

Unlike neighboring New York City, New Jersey’s healthcare ecosystem is less saturated and more interconnected. Decision-makers are accessible. Pilots can be coordinated more efficiently. Relationships can be built faster. That accessibility can make the difference between a stalled proof-of-concept and a scalable commercial partnership.

A practical state to scale

New Jersey’s compact geography allows companies to engage multiple health systems, academic centers, and payers within a short radius. Once a solution is validated here, it becomes significantly easier to expand into adjacent major markets like New York and Philadelphia — and then nationally.

Prove your model in New Jersey, and you are well-positioned to scale across the U.S.

Structured Innovation Pathways

At Hackensack Meridian Health, the Emerge Program actively identifies and pilots innovative healthcare technologies. Selected companies receive structured evaluation, clinical feedback, and system-wide exposure. For a UK firm, participation creates not only a pilot opportunity but also institutional credibility within the U.S. market. 

The state is also home to SciTech Scity, a public-private innovation campus initiative in Jersey City designed to foster hospital pilots and cross-sector collaboration. Its mission is to connect startups directly with healthcare institutions to accelerate testing and adoption.

Maternal and women’s health innovation is another area of strength in New Jersey. Collaborations with Rowan University, Cooper University Health Care, and Plug and Play create targeted opportunities for startups addressing maternal outcomes, digital monitoring, and health equity.

These sector-specific innovation channels allow UK firms to move beyond generic networking and into structured, outcomes-focused engagement.

A Life Sciences Powerhouse With Healthtech at Its Core

New Jersey has long been a global leader in pharmaceuticals and medical devices, hosting major R&D operations for multinational companies and maintaining the highest concentrations of scientists and engineers in the United States.

Healthtech companies working at the intersection of digital platforms, diagnostics, AI, and therapeutics have access to:

• Partnerships with pharmaceutical companies on digital biomarkers and trial optimization
• Collaboration on real-world evidence generation
• Access to regulatory, clinical, and commercialization expertise
• Integration with established supply chains

The proximity between health systems, pharma, device manufacturers, and academic research institutions compresses the innovation cycle. Ideas can move from pilot to partnership more efficiently in markets (like New Jersey) that are less fragmented.

Talent and Translational Research

New Jersey’s academic institutions — including standouts like Princeton University, Rutgers University, and the New Jersey Institute of Technology — contribute strength in AI, data science, engineering, and translational medicine.

This translates into access to technical co-development partners, the ability to recruit specialized STEM talent, and opportunities for joint grant funding and clinical and economic research collaborations.

Combined with workforce training programs aligned to biotechnology and healthcare operations, companies can scale U.S. teams without relocating entire functions from the UK.

Location, Logistics, and Connectivity

Strategically positioned between New York City and Philadelphia, New Jersey provides immediate access to two of the largest healthcare and financial markets in the country without the operational costs and congestion of being headquartered directly within them.

International connectivity is seamless via Newark Liberty International Airport, offering direct links to London and other major European hubs. For UK leadership teams managing transatlantic operations, ease of travel and logistics is important. New Jersey’s connectivity supports agile oversight during critical early-stage U.S. expansion.

Incentives That Reduce Risk

New Jersey strengthens its ecosystem through financial support mechanisms that lower barriers to entry for innovative companies. These include:

• R&D tax credits supporting biotech and digital health innovation
• Angel investor tax credits to stimulate early-stage capital
• Economic development incentives for job creation and facility investment

The state also provides dedicated support for international companies through Choose New Jersey and the New Jersey Europe Center, helping them navigate regulatory frameworks, site selection, and partnership development.

A Smarter First Step Into the U.S.

When expanding to the United States, entering the right state can accelerate validation, reduce commercial friction, and provide a credible base for national growth.

New Jersey offers nationally ranked hospital systems and specialty centers, one of the most diverse patient populations in the country, structured pilot and accelerator programs, deep pharmaceutical and life sciences integration, strategic Northeast corridor positioning, and practical financial incentives.

For UK healthtech innovators, the strategy is straightforward: Prove your technology in New Jersey. Build clinical credibility. Refine your U.S. go-to-market model. Then scale outward.